Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate

作者：Behdani Fatemeh; Roudbaraki Seyede Narjes; Saberi Karimian Maryam; Tayefi Maryam; Hebrani Paria; Akhavanrezayat Amir; Amlashi Sadegh Vahabi; Ferns Gordon A; Ghayour Mobarhan Majid^*

来源：Psychiatry Research, 2018, 261: 243-247.

DOI：10.1016/j.psychres.2017.12.028

• Schizophrenia
• Clozapine
• Omega-3

Omega-3 fatty acid (FA) supplementation has been reported to improve several cardio-metabolic risk factors. We aimed to assess the efficacy of omega-3 fatty acids on metabolic and inflammatory indices in patients with schizophrenia who were taking clozapine and sodium valproate. All patients were on a stable dose of 300-400 mg of clozapine for 3 months. Subjects were randomized to treatment with either omega-3 fatty acid (4 gr/day) or a placebo for 8 weeks. Height, weight, abdominal circumference, serum lipid profile, fasting blood glucose (FBG), and serum high sensitivity-C-reactive protein (hs-CRP) were determined at baseline and after 8 weeks of treatment. Fifty six subjects were recruited into the study. Patients with schizophrenia who were in the group receiving omega-3 FA capsules had an improvement in some anthropometric indices including weight, BMI, wrist and waist circumference, compared to the placebo group. Only changes in waist circumferences remained significantly different after adjustment for serum fasted TG. Our results showed omega-3 FA supplementation can improve some anthropometric indices in patients with schizophrenia who are taking clozapine pharmacotherapy.

• 出版日期2018-3